Cargando…
Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254457/ https://www.ncbi.nlm.nih.gov/pubmed/35803384 http://dx.doi.org/10.1016/j.jinf.2022.06.032 |
| _version_ | 1784740703682691072 |
|---|---|
| author | Yan, Yan Davgadorj, Chantsalmaa Lyu, Chunyan Zhang, Shiliang Qiu, Yuanwang |
| author_facet | Yan, Yan Davgadorj, Chantsalmaa Lyu, Chunyan Zhang, Shiliang Qiu, Yuanwang |
| author_sort | Yan, Yan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9254457 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92544572022-07-05 Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study Yan, Yan Davgadorj, Chantsalmaa Lyu, Chunyan Zhang, Shiliang Qiu, Yuanwang J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-10 2022-07-05 /pmc/articles/PMC9254457/ /pubmed/35803384 http://dx.doi.org/10.1016/j.jinf.2022.06.032 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Yan, Yan Davgadorj, Chantsalmaa Lyu, Chunyan Zhang, Shiliang Qiu, Yuanwang Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study |
| title | Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study |
| title_full | Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study |
| title_fullStr | Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study |
| title_full_unstemmed | Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study |
| title_short | Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study |
| title_sort | immunogenicity of a third dose of inactivated covid-19 vaccine in people living with hiv-1, hbv, and tuberculosis during the omicron variant epidemic: a cross-sectional study |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254457/ https://www.ncbi.nlm.nih.gov/pubmed/35803384 http://dx.doi.org/10.1016/j.jinf.2022.06.032 |
| work_keys_str_mv | AT yanyan immunogenicityofathirddoseofinactivatedcovid19vaccineinpeoplelivingwithhiv1hbvandtuberculosisduringtheomicronvariantepidemicacrosssectionalstudy AT davgadorjchantsalmaa immunogenicityofathirddoseofinactivatedcovid19vaccineinpeoplelivingwithhiv1hbvandtuberculosisduringtheomicronvariantepidemicacrosssectionalstudy AT lyuchunyan immunogenicityofathirddoseofinactivatedcovid19vaccineinpeoplelivingwithhiv1hbvandtuberculosisduringtheomicronvariantepidemicacrosssectionalstudy AT zhangshiliang immunogenicityofathirddoseofinactivatedcovid19vaccineinpeoplelivingwithhiv1hbvandtuberculosisduringtheomicronvariantepidemicacrosssectionalstudy AT qiuyuanwang immunogenicityofathirddoseofinactivatedcovid19vaccineinpeoplelivingwithhiv1hbvandtuberculosisduringtheomicronvariantepidemicacrosssectionalstudy |